Influence of afatinib dose on outcomes of advanced EGFR-mutant NSCLC patients with brain metastases

BMC Cancer

Table 2 Factors influencing outcomes to afatinib. The clinical factors that influenced PFS in our cohort

	No. of events/ patients	Median PFS, months (95% CI)	Log-rank p-value	Hazard ratio (95% CI)	Cox model p-value
Total	60 / 120	11.9 (10.3, 19.3)	NA	NA	NA
Sex
Male	35 / 62	13.3 (9.0, 20.1)	0.344	1	0.343
Female	25 / 58	11.9 (10.3, 25.7)		0.78 (0.47, 1.31)
Age at diagnosis, years
< 65	45 / 86	11.9 (9.7, 19.3)	0.791	1	0.790
≥ 65	15 / 34	11.7 (5.3, UD)		0.92 (0.51, 1.66)
Smoking history
Never	42 / 91	14.5 (10.7, 22.1)	0.017	1	0.025
Former / Current	18 / 29	7.9 (3.5, 17.4)		1.94 (1.12, 3.38)
EGFR mutation type
Exon 19 deletion	40 / 83	15.0 (10.9, 22.1)	< 0.001	1	0.008
L858R	12 / 27	11.2 (6.5, UD)		1.19 (0.62, 2.28)
Others	6 / 8	4.5 (1.7, UD)		5.51 (2.23, 13.64)
Brain metastasis at start of afatinib
No	40 / 80	15.0 (10.9, 20.6)	0.140	1	0.153
Yes	20 / 40	7.9 (5.1, 13.3)		1.50 (0.87, 2.57)^a
Starting dose^b
30 mg	23 / 58	10.7 (6.5, UD)	0.105	1	0.113
40 mg	37 / 61	15.0 (10.8, 20.6)		0.63 (0.36, 1.11)
Amongst patients with no brain metastasis:
Starting dose^b
30 mg	10 / 35	UD	0.897	1	0.898
40 mg	30 / 44	15.0 (10.8, 22.1)		0.95 (0.44, 2.04)
Amongst patients with brain metastasis:
Starting dose
30 mg	13 / 23	5.3 (3.1, 10.7)	0.040	1	0.041
40 mg	7 / 17	13.3 (6.5, UD)		0.39 (0.15, 0.99)
Amongst patients on 30 mg starting dose:
Brain metastasis
No	10 / 35	UD	0.007	1	0.010
Yes	13 / 23	5.3 (3.1, 10.7)		2.96 (1.29, 6.79)
Amongst patients on 40 mg starting dose:
Brain metastasis
No	30 / 44	15.0 (10.8, 22.1)	0.567	1	0.558
Yes	7 / 17	13.3 (6.5, UD)		0.79 (0.34, 1.80)^a

ISSN: 1471-2407